Literature DB >> 26212178

Changing paradigms in the systemic treatment of advanced cervical cancer.

Krista S Pfaendler1, Krishnansu S Tewari2.   

Abstract

Despite availability of primary and secondary prevention measures, cervical cancer persists as one of the most common cancers among women around the world. Although early-stage disease can be cured with radical and even fertility-sparing surgery, patients with metastatic and recurrent cervical cancer have poor prognosis with historically limited treatment options and incurable disease. Significant advances in cervical cancer treatment have emerged as the result of clinical trials that have sought to determine the best therapy to prolong overall and progression-free survival. Most recently, trials that have involved angiogenesis blockade in addition to standard chemotherapy have demonstrated improved overall and progression-free survival. This review serves to highlight pivotal trials in chemotherapy development for advanced, metastatic, and recurrent cervical cancer that includes the paradigm-shifting work that demonstrates increased overall survival with angiogenesis blockade.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antiangiogenesis; bevacizumab; cervical cancer

Mesh：

Substances：

Year:  2015        PMID： 26212178      PMCID： PMC5613936          DOI： 10.1016/j.ajog.2015.07.022

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


  33 in total

1.  Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.

Authors:  Bradley J Monk; Lini N Pandite
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

2.  A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).

Authors:  Isamu Saito; Ryo Kitagawa; Haruhiko Fukuda; Taro Shibata; Noriyuki Katsumata; Ikuo Konishi; Hiroyuki Yoshikawa; Toshiharu Kamura
Journal:  Jpn J Clin Oncol       Date:  2009-10-12       Impact factor: 3.019

3.  A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.

Authors:  Lindsey E Minion; Jiaru Bai; Bradley J Monk; L Robin Keller; Eskander N Ramez; Gareth K Forde; John K Chan; Krishnansu S Tewari
Journal:  Gynecol Oncol       Date:  2015-03-10       Impact factor: 5.482

4.  RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Authors:  Tracey Schefter; Kathryn Winter; Janice S Kwon; Kelly Stuhr; Khalid Balaraj; Brian Patrick Yaremko; William Small; William Sause; David Gaffney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

5.  Cancer statistics for Hispanics/Latinos, 2015.

Authors:  Rebecca L Siegel; Stacey A Fedewa; Kimberly D Miller; Ann Goding-Sauer; Paulo S Pinheiro; Dinorah Martinez-Tyson; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-09-16       Impact factor: 508.702

6.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.

Authors:  Bradley J Monk; Luis Mas Lopez; Juan J Zarba; Ana Oaknin; Carole Tarpin; Wichai Termrungruanglert; Jacquelyn A Alber; Jie Ding; Melissa W Stutts; Lini N Pandite
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

7.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

8.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

9.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

10.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544
View more
  57 in total

1.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

Review 2.  Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.

Authors:  Daniela Luvero; Francesco Plotti; Salvatore Lopez; Giuseppe Scaletta; Stella Capriglione; Roberto Montera; Gianina Antonelli; Sara Ciuffreda; Raffaella Carassiti; Alice Oliveti; Roberto Angioli
Journal:  Med Oncol       Date:  2017-05-05       Impact factor: 3.064

3.  Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Authors:  Stephanie Lheureux; Marcus O Butler; Blaise Clarke; Mihaela C Cristea; Lainie P Martin; Katia Tonkin; Gini F Fleming; Anna V Tinker; Hal W Hirte; Daliah Tsoref; Helen Mackay; Neesha C Dhani; Prafull Ghatage; Johanne Weberpals; Stephen Welch; Nhu-An Pham; Vinicius Motta; Valentin Sotov; Lisa Wang; Katherine Karakasis; Smitha Udagani; Suzanne Kamel-Reid; Howard Z Streicher; Patricia Shaw; Amit M Oza
Journal:  JAMA Oncol       Date:  2018-07-12       Impact factor: 31.777

4.  Cervical cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Vicki B Benard; Meg Watson; Mona Saraiya; Rhea Harewood; Julie S Townsend; Antoinette M Stroup; Hannah K Weir; Claudia Allemani
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

5.  Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.

Authors:  Mark H Einstein; Ntokozo Ndlovu; Jeannette Lee; Elizabeth A Stier; Jeffrey Kotzen; Madhur Garg; Kathleen Whitney; Shelly Y Lensing; Mariza Tunmer; Webster Kadzatsa; Joel Palefsky; Susan E Krown
Journal:  Gynecol Oncol       Date:  2019-02-15       Impact factor: 5.482

6.  Simultaneous Metastasis from Cervical Cancer to the Kidney and Paraspinal Muscle: A Case Report.

Authors:  Juliana Rodriguez; Juan C Castro; María Beltran; Oscar Forero; Rene Pareja
Journal:  Cureus       Date:  2019-02-27

Review 7.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

Review 8.  Immunotherapy in Cervical Cancer.

Authors:  Dennis Mauricio; Burak Zeybek; Joan Tymon-Rosario; Justin Harold; Alessandro D Santin
Journal:  Curr Oncol Rep       Date:  2021-04-14       Impact factor: 5.075

9.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

Review 10.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.